Quantcast
Viewing all articles
Browse latest Browse all 1030

DARTS Technology Launches New Drug Target Identification Service Designed to Streamline Drug Development

Tuesday, July 18th 2017 at 12:30pm UTC

Enables Identification of Potential Side Effects Before Trials

NEW YORK–(BUSINESS WIRE)– DARTS Sciences, Inc. (www.dartssciences.com)
has obtained an exclusive license for the DARTS patent (Drug Affinity
Responsive Target Stability Technology), and is the sole provider of the
cutting edge technology designed to streamline drug development and save
pharmaceutical and biotech companies significant time and money by
identify a drug’s target of actions, it was announced today by Dr. Jack
Kavanaugh, CEO and Chairman of the company. Dr. Kavanaugh was also the
founder and CEO of ZetaRX which became the core component of Juno
Therapeutics. Said Kavanaugh, “I believe that DARTS will revolutionize
molecular screening for therapeutic effectiveness, avoidance of
side-effects and development of beneficial applications thereby
benefitting patients.”

DARTS Sciences was founded by UCLA professor Dr. Jing Huang, who
invented the technology, Dr. Brett Lomenick, also of UCLA and COO of the
company, and Dr. Kavanaugh.

With DARTS Sciences paradigm-changing technology, pharmaceutical and
biotech companies will be able to identify therapeutic targets, predict
side-effects early in their drug development efforts and identify
repurposing targets of existing drugs. This will accelerate pre-clinical
and clinical drug discovery drug development and diagnostic development.

The ground breaking technology allows (1) unbiased proteome-wide drug
target identification using state-of-the-art proteomics and mass
spectrometry technologies, (2) specific analysis of candidate drug
targets, and (3) drug screening against any protein target of interest.
DARTS technology uses the native, unmodified drugs, complex protein
lysates from any cell or tissue type or subcellular fraction and relies
solely on the binding interaction between the drug and its target
proteins. Furthermore, DARTS is applicable to any class of compounds
regardless of structure, mechanism of action or therapeutic area and is
already providing services to customers.

Image may be NSFW.
Clik here to view.

Contacts

Andrew Freedman Public Relations
Andrew Freedman, 646-922-7223
andrew@aefpr.com

Source: DARTS Sciences, Inc.

Cet article DARTS Technology Launches New Drug Target Identification Service
Designed to Streamline Drug Development
est apparu en premier sur EEI-BIOTECHFINANCES.


Viewing all articles
Browse latest Browse all 1030

Trending Articles